X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways and is not an immunosuppressant. It is approved for the treatment of chronic spontaneous urticaria.
Lead Product(s): Dupilumab
Therapeutic Area: Immunology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab), a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways, reduced COPD exacerbations in Phase 3 trial.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab), a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways, shows positive results from a Phase 3 trial in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13), and US FDA has issued a CRL for the sBLA for Dupixent® (dupilumab) in chronic spontaneous urticaria (CSU).
Lead Product(s): Dupilumab
Therapeutic Area: Immunology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant, which is used for treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Adding Dupixent (dupilumab) to low-potency TCS improved skin clearance and reduced overall disease severity and itch compared to TCS alone at 16 weeks. Dupixent patients experienced improvement in measures of sleep quality, skin pain and health-related quality of life.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Presentations of analyses evaluating skin barrier function in patients 12 years and older will show Dupixent (dupilumab) normalized skin barrier function for many patients and was associated with improvements in disease signs and symptoms and quality of life.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab), is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent (Dupilumab) in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Long-term safety data from a 52-week open-label extension trial in this age group reinforce the well-established safety profile of Dupixent (dupilumab), observed across all other approved age groups.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent 300 mg weekly, a fully human mAB that inhibits signaling of interleukin-4 and interleukin-13 pathways, significantly improved signs and symptoms of EoE at 24 weeks compared to placebo, including ability to swallow and reduction in eosinophil count in esophagus.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis at 24 weeks compared to placebo in patients 12 years and older.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in an interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futility.
Lead Product(s): Dupilumab
Therapeutic Area: Immunology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13. IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications. The occurrences of treatment-emergent adverse events were generally similar between Dupixent and placebo groups (57% Dupixent, 51% placebo).
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent using Regeneron's proprietary VelocImmune® technology, is fully human monoclonal antibody that inhibits the signaling of IL-4 and (IL-13 pathways, a key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents, and adults.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Phase 3 trial showed Dupixent® (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Pivotal trial showed more than four times as many children achieved itch reduction and more than three times as many children achieved clear or almost clear skin with Dupixent plus topical corticosteroids (TCS) compared to TCS alone.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
DUPIXENT® is a fully humanised monoclonal antibody that inhibits signaling of IL-4 and IL-13 proteins and is not an immunosuppressant. It is the only biologic approved in Canada to treat severe asthma with type 2/eosinophilic phenotype, or oral corticosteroid-dependent asthma.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE).
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Health Canada approved a new indication for Dupixent, as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Recommendation was supported by multiple clinical trials that demonstrated superiority of Dupixent® over placebo in improving disease extent and severity, skin clearance and itch intensity, as well as health-related quality of life.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13. Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease .
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. It is being evaluated for the treatment of chronic obstructive pulmonary disease with type 2 inflammation.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. It is approved for treatment of children aged 1 year and older with eosinophilic esophagitis.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the IL-4 & IL-13 pathways. It is now approved for the treatment of atopic dermatitis with moderate-to-severe hand & foot involvement for patients aged 12 years & older.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13), and US FDA has accepted for Priority Review the sBLA for the treatment of children aged 1 to 11 years with eosinophilic esophagitis.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases.
Lead Product(s): BSI-045B,Dupilumab
Therapeutic Area: Dermatology Product Name: BSI-045B
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways and is not an immunosuppressant. It is being investigated for moderate-to-severe atopic hand and foot dermatitis.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2023
Details:
Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Immunology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Dupixent® (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
Dupilumab is an antibody that blocks, or inhibits, a receptor called interleukin (IL)-4 receptor alpha. As a result, allergic factors IL-13 and IL-4, which are important in the inflammation that EoE patients experience, are suppressed when the receptor is blocked.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
Dupixent (dupilumab), which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2022
Details:
Dupixent is an injection under the skin (subcutaneous injection) at different injection sites. In the EU for adults with prurigo nodularis, dupilumab is administered at 300 mg every two weeks, following a loading dose.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
About three times as many Dupixent (dupilumab) patients (60% and 58%) experienced a clinically meaningful reduction in itch from baseline at 24 weeks, compared to 18% and 20% for placebo, the primary endpoint in PRIME.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
Nearly three times as many Dupixent (dupilumab) patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Results from the longest global Phase 3 open-label extension trial for Dupixent® (dupilumab) in this age group in asthma show sustained improvement in lung function, low rate of asthma attacks and a consistent safety profile for up to two years.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
Dupixent (Dupilumab), which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Dupixent (dupilumab) is administered as an injection under the skin (subcutaneous injection) at different injection sites. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat EoE in the United States.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Approval based on Phase 3 data showing Dupixent (dupilumab),a fully human monoclonal antibody inhibit signaling of interleukin-4 and interleukin-13, significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Dupixent, a fully human mAB that inhibits the signaling of the IL-4 and IL-13 pathways, significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions.
Lead Product(s): Dupilumab
Therapeutic Area: Dermatology Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
